Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

- Plan Includes Shut Down of Discovery Operations and Expansion of Business

Development Activities -

LA JOLLA, Calif., Sept. 25 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it will transition from a discovery and development company to a development-only company, focusing on its three clinical development programs. As a result, TorreyPines will streamline operations through the shut down of its discovery operations, and seek to monetize non-core assets through the expansion of its business development efforts. On September 30, 2008, the company will reduce its work force by approximately 50 percent, primarily in the area of discovery. As a result of this restructuring the company expects to decrease its spending going forward. The company will retain 13 employees supporting preclinical, clinical, business development, and administrative activities.

TorreyPines' 2008 strategic plan, as presented in February 2008, is intended to maximize the value of the company's clinical stage product candidates: tezampanel, NGX426 and NGX267. By year end 2008 TorreyPines Therapeutics will:

-- Conduct an end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) to discuss the Phase III program for tezampanel in acute migraine headache. The end-of-Phase II meeting with the FDA is scheduled for September 29th. As reported in October 2007, tezampanel, an AMPA/kainate receptor antagonist, met its primary endpoint of headache pain relief in a double-blind, placebo-controlled Phase IIb trial in 306 patients with acute migraine headache. This trial marked the sixth clinical study demonstrating tezampanel's effectiveness in the treatment of chronic pain.

-- Co
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Annualized Relapse Rate and was Well Tolerated in MS Patients -- PARIS, August 30, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc. (OTC Bulletin Board: GOVX ), a biotechnology ... announced the results of its Annual Shareholders Meeting, held on ... seven nominees for directors of the company to serve until ... are duly elected or appointed and qualified. They are: ...
... Bioheart, Inc., (OTC Bulletin Board: BHRT ) ... with stem cell therapy on the first two congestive ... Angeles Tijuana through its Center of Excellence, Regenerative Medicine ... an agreement to establish a Center of Excellence for ...
Cached Biology Technology:Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... stem cells can stimulate neurogenesis in the brain of ... and improve tissue and function injury under the condition ... therapeutic effect of adipose-derived stem cells (ADSCs) transplantation in ... injury and neurogenesis in the brain of AD mice. ... Sciences, Tsinghua University, China transplanted ADSCs into the hippocampus ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "International Biometrics Technology Market - Industry Analysis ... report to their offering. ... attacks and crimes has created a need for high ... methods used for personnel authentication such as username and ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... ARBORA common test used to determine mercury exposure from ... the toxic metal released from fillings, according to University ... fillings slowly release mercury vapor into the mouth. But ... of whether this exposure presents a significant health risk ...
... process that releases the energy in coal without burning ... passed a milestone on the route to possible commercial use, ... Energy & Fuels describes results of a successful 200-hour ... two inexpensive but highly polluting forms of coal. ...
... 2013) - House paint containing dangerous,concentrations of lead is ... and the,company is refusing to remove the paint from ... regulations to restrict the lead content of paint in,Cameroon ... of,Occupational Knowledge International (OK International) and co-author of a ...
Cached Biology News:Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3US company identified as manufacture of lead paint in Africa 2